Navigating the complex landscape of benzodiazepine- and Z-drug diversity: insights from comprehensive FDA adverse event reporting system analysis and beyond

INTRODUCTION: Medications which target benzodiazepine (BZD) binding sites of GABAA receptors (GABAARs) have been in widespread use since the nineteen-sixties. They carry labels as anxiolytics, hypnotics or antiepileptics. All benzodiazepines and several nonbenzodiazepine Z-drugs share high affinity...

Descripción completa

Detalles Bibliográficos
Autores principales: Koniuszewski, Filip, Vogel, Florian D., Dajić, Irena, Seidel, Thomas, Kunze, Markus, Willeit, Matthäus, Ernst, Margot
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Psychiatry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10345211/
https://www.ncbi.nlm.nih.gov/pubmed/37457785
http://dx.doi.org/10.3389/fpsyt.2023.1188101

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10345211/
https://www.ncbi.nlm.nih.gov/pubmed/37457785
http://dx.doi.org/10.3389/fpsyt.2023.1188101

Ejemplares similares